Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-20T05:21:06.812Z Has data issue: false hasContentIssue false
  • English
  • Français

Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori for management of dyspepsia: A randomized trial in primary care

Published online by Cambridge University Press:  09 August 2006

Dorte Ejg Jarbol ,
Mickael Bech ,
Jakob Kragstrup ,
Troels Havelund  and
Ove B. Schaffalitzky de Muckadell
Dorte Ejg Jarbol
Affiliation:
University of Southern Denmark
Mickael Bech
Affiliation:
University of Southern Denmark
Jakob Kragstrup
Affiliation:
University of Southern Denmark
Troels Havelund
Affiliation:
University of Southern Denmark and Odense University Hospital
Ove B. Schaffalitzky de Muckadell
Affiliation:
University of Southern Denmark and Odense University Hospital
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: An economic evaluation was performed of empirical antisecretory therapy versus test for Helicobacter pylori in the management of dyspepsia patients presenting in primary care.

Methods: A randomized trial in 106 general practices in the County of Funen, Denmark, was designed to include prospective collection of clinical outcome measures and resource utilization data. Dyspepsia patients (n=722) presenting in general practice with more than 2 weeks of epigastric pain or discomfort were managed according to one of three initial management strategies: (i) empirical antisecretory therapy, (ii) testing for Helicobacter pylori, or (iii) empirical antisecretory therapy, followed by Helicobacter pylori testing if symptoms improved. Cost-effectiveness and incremental cost-effectiveness ratios of the strategies were determined.

Results: The mean proportion of days without dyspeptic symptoms during the 1-year follow-up was 0.59 in the group treated with empirical antisecretory therapy, 0.57 in the H. pylori test-and-eradicate group, and 0.53 in the combination group. After 1 year, 23 percent, 26 percent, and 22 percent, respectively, were symptom-free. Applying the proportion of days without dyspeptic symptoms, the cost-effectiveness for empirical treatment, H. pylori test and the combination were 12,131 Danish kroner (DKK), 9,576 DKK, and 7,301 DKK, respectively. The incremental cost-effectiveness going from the combination strategy to empirical antisecretory treatment or H. pylori test alone was 54,783 DKK and 39,700 DKK per additional proportion of days without dyspeptic symptoms.

Conclusions: Empirical antisecretory therapy confers a small insignificant benefit but costs more than strategies based on test for H. pylori and is probably not a cost-effective strategy for the management of dyspepsia in primary care.

Keywords

DyspepsiaHelicobacter pyloriHealthcare costsPrimary health careAntiulcer agents
Type
GENERAL ESSAYS
Information
International Journal of Technology Assessment in Health Care , Volume 22 , Issue 3 , July 2006 , pp. 362 - 371
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agreus L, Borgquist L. 2002 The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics. 20: 347– 355.Google Scholar
Agreus L, Svardsudd K, Nyren O, Tibblin G. 1994 The epidemiology of abdominal symptoms: Prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. Scand J Gastroenterol. 29: 102– 109.Google Scholar
Agreus L, Svardsudd K, Nyren O, Tibblin G. 1995 Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology. 109: 671– 680.Google Scholar
Allison JE, Hurley LB, Hiatt RA, et al. 2003 A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: Clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med. 163: 1165– 1171.Google Scholar
Arents NL, Thijs JC, van Zwet AA, et al. 2003 Approach to treatment of dyspepsia in primary care: A randomized trial comparing “test-and-treat” with prompt endoscopy. Arch Intern Med. 163: 1606– 1612.Google Scholar
Axon AT, O'Morain CA, Bardhan KD, et al. 1997 Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. BMJ. 314: 565– 568.Google Scholar
Bech M, Gyrd-Hansen D. 2000 Cost implications of routine mammography screening of women 50-69 years in the county of Funen, Denmark. Health Policy. 54: 125– 141.Google Scholar
Blum AL, Talley NJ, O'Morain C, et al. 1998 Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med. 339: 1875– 1881.Google Scholar
Briggs A, Andrew H. 2001. Handling uncertainty in economics evaluation and presenting the results. In: Drummond M, McGuire A, eds. Oxford: Oxford University Press;
Briggs A, Sculpher M, Buxton M. 1994 Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ 3: 95– 104.Google Scholar
Briggs AH, Sculpher MJ, Logan RP, et al. 1996 Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ. 312: 1321– 1325.Google Scholar
Briggs AH, Wonderling DE, Mooney CZ. 1997 Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ. 6: 327– 340.Google Scholar
Bruley D, V, Flejou JF, Colin R, et al. 2001 There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 15: 1177– 1185.Google Scholar
Bytzer P. 2004 Diagnostic approach to dyspepsia. Best Pract Res Clin Gastroenterol. 18: 681– 693.Google Scholar
Bytzer P, Aalykke C, Rune S, et al. 2000 Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group. Scand J Gastroenterol. 35: 1023– 1032.Google Scholar
Bytzer P, Talley NJ. 2001 Dyspepsia. Ann Intern Med. 134: 815– 822.Google Scholar
Chey WD, Moayyedi P. 2004 Uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther. 19 (Suppl 1): 1– 8.Google Scholar
Chiba N, Van Zanten SJ, Sinclair P, et al. 2002 Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ. 324: 1012– 1016.Google Scholar
Chiba N, Veldhuyzen van Zanten SJ, Escobedo S, et al. 2004 Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. Aliment Pharmacol Ther. 19: 349– 358.Google Scholar
Ciociola AA, McSorley DJ, Turner K, et al. 1999 Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol. 94: 1834– 1840.Google Scholar
Delaney B, Moayyedi P, Deeks J, et al. 2000 The management of dyspepsia: A systematic review. Health Technol Assess. 4: iii– 189.Google Scholar
Delaney BC. 2003 Dyspepsia management in the millennium: To test and treat or not? Gut. 52: 10– 11.Google Scholar
Delaney BC, Ford AC, Forman D, et al. 2005 Initial management strategies for dyspepsia. Cochrane Database Syst Rev. CD001961.Google Scholar
Delaney BC, Moayyedi P, Logan RF. 2003 Dyspepsia results may not apply in primary care. BMJ. 327: 811.Google Scholar
Dimenas E, Glise H, Hallerback B, et al. 1995 Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 30: 1046– 1052.Google Scholar
Ebell MH, Warbasse L, Brenner C. 1997 Evaluation of the dyspeptic patient: A cost-utility study. J Fam Pract. 44: 545– 555.Google Scholar
Farkkila M, Sarna S, Valtonen V, Sipponen P. 2004 Does the ‘test-and-treat’ strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. Scand J Gastroenterol. 39: 327– 335.Google Scholar
Fendrick AM, Chernew ME, Hirth RA, Bloom BS. 1995 Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med. 123: 260– 268.Google Scholar
Fennerty MB. 2002 Review article: Helicobacter pylori and uninvestigated dyspepsia. Aliment Pharmacol Ther. 16 (Suppl 1): 52– 57.Google Scholar
Fenwick E, O'Brien BJ, Briggs A. 2004 Cost-effectiveness acceptability curves–facts, fallacies and frequently asked questions. Health Econ. 13: 405– 415.Google Scholar
Forbes GM, Glaser ME, Cullen DJ, et al. 1994 Duodenal ulcer treated with Helicobacter pylori eradication: Seven-year follow-up. Lancet. 343: 258– 260.Google Scholar
Froehlich F, Gonvers JJ, Wietlisbach V, et al. 2001 Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. Am J Gastroenterol. 96: 2329– 2336.Google Scholar
Garcia-Altes A, Jovell E. 2001 Economic analysis of treatment of functional dyspepsia. An assessment of the quality of published studies. Int J Technol Assess Health Care. 17: 517– 527.Google Scholar
Graham DY, Lew GM, Klein PD, et al. 1992 Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 116: 705– 708.Google Scholar
Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB. 1998 Management of dyspeptic patients in primary care. Value of the unaided clinical diagnosis and of dyspepsia subgrouping. Scand J Gastroenterol. 33: 799– 805.Google Scholar
Heading RC. 1999 Prevalence of upper gastrointestinal symptoms in the general population: A systematic review. Scand J Gastroenterol Suppl. 231: 3– 8.Google Scholar
Heikkinen M, Pikkarainen P, Takala J, Julkunen R. 1996 General practitioners' approach to dyspepsia. Survey of consultation frequencies, treatment, and investigations. Scand J Gastroenterol. 31: 648– 653.Google Scholar
Heikkinen M, Pikkarainen P, Takala J, et al. 1995 Etiology of dyspepsia: Four hundred unselected consecutive patients in general practice. Scand J Gastroenterol. 30: 519– 523.Google Scholar
Hopkins RJ, Girardi LS, Turney EA. 1996 Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology. 110: 1244– 1252.Google Scholar
Hsu PI, Lai KH, Tseng HH, et al. 2001 Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther. 15: 195– 201.Google Scholar
Jarbol DE, Kragstrup J, Stovring H, et al. 2006 Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. Am J Gastroenterol. in press.Google Scholar
Jones R, Lydeard S. 1989 Prevalence of symptoms of dyspepsia in the community. BMJ. 298: 30– 32.Google Scholar
Jones RH, Lydeard SE, Hobbs FD, et al. 1990 Dyspepsia in England and Scotland. Gut. 31: 401– 405.Google Scholar
Kay L, Jorgensen T. 1994 Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors. Scand J Gastroenterol. 29: 2– 6.Google Scholar
Kernick D. 2000 Costing interventions in primary care. Fam Pract. 17: 66– 70.Google Scholar
Kernick DP, Netten A. 2002 A methodological framework to derive the cost of the GP consultation. Fam Pract. 19: 500– 503.Google Scholar
Knill-Jones RP. 1991 Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol Suppl. 182: 17– 24.Google Scholar
Koelz HR, Arnold R, Stolte M, et al. 2003 Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: A double blind randomised trial with a six month follow-up. Gut. 52: 40– 46.Google Scholar
Koopmanschap MA, Rutten FF. 1996 A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 10: 460– 466.Google Scholar
Koopmanschap MA, Rutten FF. 1996 The consequence of production loss or increased costs of production. Med Care. 34: DS59– DS68.Google Scholar
Kristiansen IS, Gyrd-Hansen D. 2004 Cost-effectiveness analysis based on the number-needed-to-treat: Common sense or non-sense? Health Econ. 13: 9– 19.Google Scholar
Ladabaum U, Chey WD. 2002 Uninvestigated Dyspepsia. Curr Treat Options Gastroenterol. 5: 125– 131.Google Scholar
Ladabaum U, Chey WD, Scheiman JM, Fendrick AM. 2002 Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: A cost-minimization analysis. Aliment Pharmacol Ther. 16: 1491– 1501.Google Scholar
Ladabaum U, Fendrick AM, Glidden D, Scheiman JM. 2002 Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States. Am J Gastroenterol. 97: 3007– 3014.Google Scholar
Laheij RJ, Severens JL, Jansen JB, et al. 1997 Management in general practice of patients with persistent dyspepsia. A decision analysis. J Clin Gastroenterol. 25: 563– 567.Google Scholar
Laine L, Schoenfeld P, Fennerty MB. 2001 Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med. 134: 361– 369.Google Scholar
Lassen A, Hallas J, de Muckadell OB. 2003 Eradication of Helicobacter pylori and use of antisecretory drugs: Population based cohort study. BMJ. 327: 603.Google Scholar
Lassen AT, Hallas J, Schaffalitzky de Muckadell OB. 2004 Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. Gut. 53: 1758– 1763.Google Scholar
Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. 2000 Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: A randomised trial. Lancet. 356: 455– 460.Google Scholar
Leodolter A, Kulig M, Brasch H, et al. 2001 A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 15: 1949– 1958.Google Scholar
Makris N, Barkun A, Crott R, Fallone CA. 2003 Cost-effectiveness of alternative approaches in the management of dyspepsia. Int J Technol Assess Health Care. 19: 446– 464.Google Scholar
Malfertheiner P, Megraud F, O'Morain C et al. 2002 Current concepts in the management of Helicobacter pylori infection–the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 16: 167– 180.Google Scholar
Mandelblatt JS, Fryback DG, Weinstein MC, et al. 1997 Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med. 12: 551– 558.Google Scholar
Manes G, Menchise A, De Nucci C, Balzano A. 2003 Empirical prescribing for dyspepsia: Randomised controlled trial of test and treat versus omeprazole treatment. BMJ. 326: 1118.Google Scholar
Marshall BJ, Goodwin CS, Warren JR, et al. 1988 Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 2: 1437– 1442.Google Scholar
McColl K, Murray L, El Omar E, et al. 1998 Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 339: 1869– 1874.Google Scholar
McColl KE, Dickson A, El Nujumi A, et al. 2000 Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: Impact of gastroesophageal reflux disease. Am J Gastroenterol. 95: 101– 105.Google Scholar
McColl KE, Murray LS, Gillen D, et al. 2002 Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ. 324: 999– 1002.Google Scholar
Miwa H, Hirai S, Nagahara A, et al. 2000 Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther. 14: 317– 324.Google Scholar
Moayyedi P, Soo S, Deeks J, et al. 2005 Eradication of Helicobacter pylori for non-ulcer dyspepsia (Cochrane Review). Cochrane Database Syst Rev. (1) CD002096.Google Scholar
Nyren O, Adami HO, Gustavsson S, Loof L. 1986 Excess sick-listing in nonulcer dyspepsia. J Clin Gastroenterol. 8: 339– 345.Google Scholar
Nyren O, Lindberg G, Lindstrom E, et al. 1992 Economic costs of functional dyspepsia. Pharmacoeconomics. 1: 312– 324.Google Scholar
Ofman JJ, Etchason J, Fullerton S, et al. 1997 Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: Clinical and economic consequences. Ann Intern Med. 126: 280– 291.Google Scholar
Olsen AD. 1998 Combined empiric treatment and specific H. Pylori screening and treatment decrease the cost of evaluating epigastric abdominal pain. Gastroenterology. 114: A248.Google Scholar
Penston JG, Pounder RE. 1996 A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther. 10: 83– 89.Google Scholar
Peura DA. 2000 The problem of Helicobacter pylori-negative idiopathic ulcer disease. Baillieres Best Pract Res Clin Gastroenterol. 14: 109– 117.Google Scholar
Rabeneck L, Wray NP, Graham DY. 1998 Managing dyspepsia: What do we know and what do we need to know? Am J Gastroenterol. 93: 920– 924.Google Scholar
Rothenbacher D, Brenner H. 2003 Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: Recent developments and future implications. Microbes Infect. 5: 693– 703.Google Scholar
Savarino V, Vigneri S, Celle G. 1999 The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut. 45 (Suppl 1): I18– I22.Google Scholar
Severens JL, Laheij RJ, Jansen JB, et al. 1998 Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther. 12: 919– 923.Google Scholar
Silverstein MD, Petterson T, Talley NJ. 1996 Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: A decision analysis. Gastroenterology. 110: 72– 83.Google Scholar
Spiegel BM, Vakil NB, Ofman JJ. 2002 Dyspepsia management in primary care: A decision analysis of competing strategies. Gastroenterology. 122: 1270– 1285.Google Scholar
Stevens VJ, Shneidman RJ, Johnson RE, et al. 2002 Helicobacter pylori eradication in dyspeptic primary care patients: A randomized controlled trial of a pharmacy intervention. West J Med. 176: 92– 96.Google Scholar
Talley NJ. 2002 Dyspepsia management in the millennium: The death of test and treat? Gastroenterology. 122: 1521– 1525.Google Scholar
Talley NJ, Axon A, Bytzer P, et al. 1999 Management of uninvestigated and functional dyspepsia: A Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther. 13: 1135– 1148.Google Scholar
Talley NJ, Janssens J, Lauritsen K, et al. 1999 Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ. 318: 833– 837.Google Scholar
Talley NJ, Silverstein MD, Agreus L, et al. 1998 AGA technical review: Evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology. 114: 582– 595.Google Scholar
Talley NJ, Vakil N, Ballard ED, Fennerty MB. 1999 Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 341: 1106– 1111.Google Scholar
Tan AC, Hartog GD, Mulder CJ. 1999 Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication. Aliment Pharmacol Ther. 13: 1519– 1522.Google Scholar
Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, et al. 1999 Design of treatment trials for functional gastrointestinal disorders. Gut. 45 (Suppl 2): II69– II77.Google Scholar
Ware JE Jr. 2000 SF-36 health survey update. Spine. 25: 3130– 3139.Google Scholar
Westbrook JI, Duggan AE, McIntosh JH. 2001 Prescriptions for antiulcer drugs in Australia: Volume, trends, and costs. BMJ. 323: 1338– 1339.Google Scholar
Xia HH, Phung N, Altiparmak E, et al. 2001 Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998. Dig Dis Sci. 46: 2716– 2723.Google Scholar